Chardan Capital analyst Keay Nakae maintained a Buy rating on AB Science SA (ABSCF – Research Report) today and set a price target of EUR10.00. The company’s shares closed last Monday at $5.90, equals to its 52-week high of $5.90.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of 2.6% and a 44.9% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Emergent Biosolutions, and Arrowhead Research.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AB Science SA with a $11.07 average price target.
The company has a one-year high of $5.90 and a one-year low of $3.85. Currently, AB Science SA has an average volume of 1,778.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AB Science SA engages in the research, development, and sales of protein kinase inhibitor drugs. It develops pharmaceutical products for the treatment of cancer, neurological, and inflammatory diseases. The firm also engages in the field of veterinary medicine.